Andreu Costa

college of pharmacy dalhousie university halifax nova scotia canada
Country flagCanada

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (14)

Year:

2026

Year:

2026

Introduction: The carbon footprint of imaging equipment in radiology is high, but the impact of patient travel for imaging is unclear. This study aimed to quantify distances traveled by ambulatory patients for outpatient MRI, determine the proportion traveling beyond their nearest MRI facility, and estimate the associated excess carbon dioxide equivalent (CO 2 e) emissions. Methods: With research ethics board approval, we retrospectively analyzed provincial MRI data from 2023. Distances from patient home address to the nearest and attended MRI facilities were calculated. CO 2 e estimates were derived using an online tool ( www.carbonfootprint.com/calculator.aspx ) with average vehicle size and emissions. Results: In 2023, 40 062 provincial MRI scans were performed; isolating single visits for adult patients yielded 27 755 data points. Of these, 19.5% (n = 5400) traveled beyond their nearest MRI facility. Mean round-trip travel was 60.4 km for those attending their nearest site versus 295.6 km for those traveling further ( P < .0001). The excess travel produced ~288 metric tons of additional CO 2 e, equivalent to emissions from 61 large-size gasoline-powered cars driven for 1 year or carbon sequestered by 4762 tree seedlings grown for 10 years. Conclusion: Nearly one-fifth of patients traveled farther than necessary for MRI, generating substantial avoidable emissions. Aligning MRI service distribution with population density could lessen the environmental impact of medical imaging.

Year:

2026

Year:

2026

The Canadian Association of Radiologists (CAR) metabolic dysfunction-associated steatotic liver disease (MASLD) Working Group (WG) is a multidisciplinary working group composed of radiologists, hepatologists, and family physicians. In this 3-part series, we provide Delphi consensus-based guidance on clinical and imaging findings for patients with known or suspected MASLD (formerly termed non-alcoholic fatty liver disease or NAFLD). Part 1 focuses on the detection and grading of hepatic steatosis on imaging; Part 2 on risk-stratification of patients with MASLD, including a patient pathway that incorporates serological and imaging investigations; and Part 3 on the implementation of practice recommendations for quality assurance using shear wave elastography (SWE) and magnetic resonance elastography (MRE) for disease staging. In the first part of these guidelines, we provide 17 guidance statements for detection, grading, and surveillance of hepatic steatosis using ultrasound (US), CT, or MRI. In addition to conventional B-mode US, we review current evidence on semi-quantitative and quantitative US techniques and provide guidance for appropriate indications and recommended technique.

Year:

2025

The Canadian Association of Radiologists (CAR) metabolic dysfunction-associated steatotic liver disease (MASLD) Working Group (WG) is a multidisciplinary working group composed of radiologists, hepatologists, and family physicians. In this 3-part series, we provide Delphi consensus-based guidance on clinical and imaging findings for patients with known or suspected MASLD (formerly termed nonalcoholic fatty liver disease or NAFLD). Part 1 focuses on the detection and grading of hepatic steatosis on imaging; Part 2 on risk-stratification of patients with MASLD, including a patient pathway using serological and imaging investigations; and Part 3 on the implementation of practice recommendations for quality assurance using shear wave elastography (SWE) and magnetic resonance elastography (MRE) programs. In Part 2 of these guidelines, the WG provides 14 recommendations for risk stratifying MASLD patients into low and high risk for advanced hepatic fibrosis ( F ≥ 3) using a combination of serological and imaging investigations. Population screening and risk stratification of MASLD patients using a clinical and serological investigation (FIB-4) followed by imaging pathway is recommended. Clinical, technical, and grading recommendations for point shear wave elastography (pSWE), 2-dimensional SWE (2D-SWE), and MRE are discussed.

Year:

2025

The Canadian Association of Radiologists (CAR) metabolic dysfunction-associated steatotic liver disease (MASLD) Working Group (WG) is a multidisciplinary working group composed of radiologists, hepatologists, and family physicians. In this 3-part series, we provide Delphi consensus-based guidance on clinical and imaging findings for patients with known or suspected MASLD (formerly termed nonalcoholic fatty liver disease or NAFLD). Part 1 focuses on the detection and grading of hepatic steatosis on imaging; Part 2 on risk stratification of patients with MASLD, including a patient pathway that applies blood-based and imaging-based investigations; and Part 3 on the implementation of practice recommendations for quality assurance using shear wave elastography (SWE) and magnetic resonance elastography (MRE) for disease staging. In the third part of these guidelines, the WG provides 18 recommendations for standardized implementation, remuneration, and quality assurance for SWE and MRE programs. Structured reporting templates for standardized SWE and MRE are provided. Introductory training presentations for technologists and radiologists are also provided. The goal of these guidelines is to enable standardized image-based screening and risk stratification of patients with MASLD across Canada.

Year:

2025

The American College of Radiology Liver Imaging Reporting and Data System (LI‐RADS) is the preeminent framework for classification and risk stratification of liver observations on imaging in patients at high risk for hepatocellular carcinoma. In this review, the pathogenesis of hepatocellular carcinoma and the use of MRI in LI‐RADS is discussed, including specifically the LI‐RADS diagnostic algorithm, its components, and its reproducibility with reference to the latest supporting evidence. The LI‐RADS treatment response algorithms are reviewed, including the more recent radiation treatment response algorithm. The application of artificial intelligence, points of controversy, LI‐RADS relative to other liver imaging systems, and possible future directions are explored. After reading this article, the reader will have an understanding of the foundation and application of LI‐RADS as well as possible future directions.

Year:

2025

Introduction: This study aimed to determine the positive predictive value (PPV) of magnetic resonance imaging–transrectal ultrasound (MRI-TRUS) machine fusion prostate biopsies, and to identify factors associated with a positive biopsy. Methods: With ethics approval, we retrospectively evaluated all MRI-TRUS machine fusion prostate biopsies at our institution from September 2022 to April 2025. True positive clinically significant prostate cancers (csPCa) were defined as Gleason ≥7. PPVs were calculated overall and for PI-RADS 3, 4 and 5 categories. A generalized linear mixed model (GLMM) was created evaluating the following factors as fixed effects: PI-RADS category; prostate-specific antigen (PSA) density (<0.10, 0.10-0.15, ≥0.15 ng/mL 2 ); lesion size (<7, 7-15, ≥15 mm); lesion location (peripheral vs transition zone); ultrasound correlate (present/absent); prostate size (<60 vs ≥60 mL); interval from MRI to biopsy (<6 months or not); and biopsy operator (2 radiologists). Referring urologist (n = 19) and reporting radiologist (n = 8) were included as random effects. Results: 372 patients (mean age, 67 ± 7 years) with 529 lesions underwent biopsy. The overall PPV was 314/529 (59.4%). For PI-RADS 3 to 5, PPVs were 32/72 (44.4%), 123/243 (50.6%), and 159/214 (74.3%), respectively. In GLMM analysis, PI-RADS 5 versus 3 (OR 3.6, 95% CI, 1.7-7.4), PSA density ≥0.15 ng/mL 2 (OR 2.2, 95% CI, 1.2-3.8), and presence of an ultrasound correlate (OR 2.7, 95% CI, 1.7-4.2) were associated with true positive biopsies. Small lesion size <7 mm was associated with a false positive biopsy (OR 0.4, 95% CI, 0.2-0.8). Conclusion: The yield of fusion prostate biopsies at our institution is high. PI-RADS 5, PSA density ≥0.15 ng/mL 2 , and an ultrasound correlate at biopsy were associated with csPCa, whereas sub-7 mm lesions were negatively associated with csPCa.

Year:

2025

Contrast media, including iodinated contrast media and gadolinium-based contrast agents, are commonly administered pharmaceuticals with excellent safety profiles. However, a minority of the population may experience a hypersensitivity reaction following intravenous administration. Hypersensitivity reactions can be immediate or delayed, and range from mild, such as urticaria, to severe, including anaphylaxis. There is emerging evidence that longstanding pretreatment protocols, such as diphenhydramine and corticosteroids, are ineffective and have the potential for side effects and other harms. Moreover, the evidence for efficacy on which this practice is based is weak and outdated. A joint collaborative working group of representatives from the Canadian Association of Radiologists and the Canadian Society of Allergy and Clinical Immunology was assembled to inform medical professionals and hospital policies regarding hypersensitivity reactions to contrast media. The objectives of the working group were to provide an overview of the epidemiology, physiology, risk factors, and types of hypersensitivity reactions; to synthesize the evidence for pretreatment strategies that minimize the risk of a breakthrough reaction for both iodinated contrast media and gadolinium-based contrast agents; to review the allergy investigations used to evaluate patients with a history of severe hypersensitivity reaction; and to provide an overview of existing guidelines. Following appraisal of the evidence, the working group established recommendations based on consensus in this practice guidance.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Collaborators (7)

Marco Dioguardi Burgio

Université Paris Cité

FRANCE
View details

Christian B. van der Pol

-

CANADA
View details

Hyo-Jin Kang

Seoul National University Hospital

SOUTH KOREA
View details

Matthew D.F. McInnes

University of Ottawa

CANADA
View details

An Tang

Full Professor with tenure

Université de Montréal

CANADA
View details

Jérémy Dana

Assistant Professor

-

FRANCE
View details

Ana-Maria Copaescu

Assistant Professor

McGill University Health Centre

CANADA
View details